- Imperial College of London review suggests that cannabis-based medicinal products offer significant relief from intractable epilepsy
- CNSC produces proprietary CBD products under the Xceptol brand that are created with branded Technology CiBiDinol that increases absorbability, bioavailability, shelf life
- Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products
Researchers from the Imperial College of London recently conducted a review that examined the impact of cannabis-based medicinal products containing cannabidiol (“CBD”) on the frequency of epileptic seizures and determined that they offer patients significant relief from intractable epilepsy (https://ibn.fm/TDwpd). As scientific evidence supporting the use of CBD becomes mainstream, concerns about absorbability, shelf life and bioavailability continue to mount. CannAssist International (OTCQB: CNSC) is dedicated to addressing these problems through the creation of CBD products using their branded technology CiBiDinol specifically created to overcome these critical issues. Marketed under the Xceptol consumer brand, CNSC’s line of products promise increased efficacy, absorption and bioavailability for superior results and efficiency per dose.
Treating epilepsy using CBD is not a new phenomenon. One of the best-known cases dates back to 2012 and concerns Charlotte Figi, a little girl who suffered up to 300 grand mal seizures per week that kept her confined to a wheelchair. The use of CBD oil to treat her condition reduced the number of seizures to 2-3 per month and sparked the medical marijuana movement that catalyzed the lifting of prohibitions on cannabis-based products throughout the United States (https://ibn.fm/dy5YL). The Imperial College of London review mirrors those results through a study that reported a 97% reduction in the monthly frequency of seizures when patients received whole-plant extract cannabis treatment.
“Patients and their families deserve better, so we implore policy makers, regulators and public health bodies to prioritize the health of these individuals and help them to access in the NHS medicines which are making a dramatic improvement to their lives,” said Rayyan Zafar, a Ph.D. candidate in the Department of Brain Sciences at the Imperial College of London (https://ibn.fm/NIb3h).
Quality is a primary concern among consumers of CBD, particularly as it enters the mainstream to include new users across a wide range of demographics. CNSC uses a quality-focused proprietary process where CBD molecules are combined with penetration-enhancing cyclodextrin in order to modify the surface of the molecule and render it water dispersible. Besides enhanced potency, Xceptol products were found via third-party testing to have a 400% increase in skin penetration along with a 300% increase in the rate of gut absorption when compared to regular oil-based CBD (https://ibn.fm/PgOMt).
Established in May 2017, CannAssist is headquartered in San Diego, California. The company’s Xceptol products are also sold online through the Range Me product marketplace and multiple international sales channels that include Central America, South America, South Africa, the EU, the UK and the Philippines.
For more information, visit the company’s website at www.CannAssistInternational.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.